#Biotherapy
Text
Biotherapy (バイオセラピー) , 1986
#Biotherapy#1986#80's horror#trash#horror#gif#film#monster#japan#j-horror#retro#vintage#splatterpunk#alien
83 notes
·
View notes
Text
Biotherapy International
В клинике Biotherapy International мы применяем последние фундаментальные научные достижения, чтобы помочь пациентам выздороветь и сохранить при этом высокое качество жизни.
1 note
·
View note
Text
Burrowing Death Cleaners
A newly-discovered function for immune cells called neutrophils as the main clearers of cells undergoing the normal process of programmed death (apoptosis) daily in the liver. Unlike other cell types responsible for clearing the body's apoptosing cells which engulf, these neutrophils burrow in and dispose of the worn-out cell from the inside
Read the published research paper here
Image from work by Lixiang Ma, Juan Zhao and Xiangyu Wang, and colleagues
Department of Neurosurgery, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
Image originally published with a Creative Commons Attribution 4.0 International (CC BY 4.0)
Published in eLife, September 2023
You can also follow BPoD on Instagram, Twitter and Facebook
6 notes
·
View notes
Text
Researchers develop technique to synthesize water-soluble alloy nanoclusters
In recent years, ultrasmall metal nanoclusters have unlocked advances in fields ranging from bioimaging and biosensing to biotherapy, thanks to their unique molecular-like properties.
In a study published in the journal Polyoxometalates, a research team from Qingdao University of Science and Technology proposed a design to synthesize atomically precise, water-soluble alloy nanoclusters.
"The novelty of this study is in a new strategy for the synthesis of water-soluble alloy nanoclusters and a further contribution to the fundamental understanding of the alloying mechanism of metal nanoclusters," said study author Xun Yuan from Qingdao University of Science and Technology.
"The ultimate goal is to develop such alloy nanoclusters as novel nanomedicine," Yuan said.
Read more.
6 notes
·
View notes
Photo
@almoosahospital: Almoosa laboratory is designed with excellence in mind to serve the Ahsa community’s diagnostic needs. The Almoosa laboratory operates at a high level of accuracy and is accredited by the College of American Pathologists (CAP), the Association for the Advancement of Blood & Biotherapies (AABB), and Saudi Food and Drug Authority S-FDA (Good Manufacturing Practice (GMP). The laboratory at Almoosa Specialist Hospital covers 2000 square meters with a state-of-the-art, fully automated core laboratory, and a reference laboratory for other regional hospitals, clinics, and laboratories. At Almoosa, State-of-the-art automated laboratory There are NO ERRORS; samples are sorted and treated automatically without human intervention to achieve outcomes beyond human capabilities. #ksa #hospital #saudiarabia #архитектура www.amazingarchitecture.com ✔ A collection of the best contemporary architecture to inspire you. #design #architecture #amazingarchitecture #architect #arquitectura #luxury #realestate #life #cute #architettura #interiordesign #photooftheday #love #travel #construction #furniture #instagood #fashion #beautiful #archilovers #home #house #amazing #picoftheday #architecturephotography #معماری (at Saudi Arabia) https://www.instagram.com/p/ChxDBnDLH1n/?igshid=NGJjMDIxMWI=
#ksa#hospital#saudiarabia#архитектура#design#architecture#amazingarchitecture#architect#arquitectura#luxury#realestate#life#cute#architettura#interiordesign#photooftheday#love#travel#construction#furniture#instagood#fashion#beautiful#archilovers#home#house#amazing#picoftheday#architecturephotography#معماری
9 notes
·
View notes
Text
Medical/Life Update
Sup duders so I haven't posted a ton of personal info here in awhile but the past 6 months have been wild. Starting in December 2021 I've had a fluctuating rash on my arms, legs, and trunk that at first I thought was an allergic reaction, hence my post about having the worst "hives" ever on Christmas. After an emergency room trip on New Years Eve and month of phone tag I finally got referred to a rheumatologist in February and diagnosed with Henoch-Schonlein Purpura (HSP) also known as IgA vasculitis. Which is an autoimmune disease more common in children but super rare in adults where the blood vessels in your skin and internal organs/joints become inflamed. Usually it goes away in a few months and leaves no lasting effects which is good.
Except now it's June and it hasn't gone away. In fact, at my last rheumatology appointment 2 weeks ago they said my inflammation markers in my blood have started going up again instead of down so we may need to move on to more intense treatment. For the past few months I've been taking a steroid (prednisone) and an immunosuppressant (mycophenolate) to hopefully counteract my dumb immune system, which has made my flare ups less intense than they were in Dec-Feb pre treatment. But even as they've increased the immunosuppressant my skin has not been totally clear in over six months and every time I so much as step outside my apartment, walk around too much, or wear tight clothing I have massive flare ups. The rash itself is not painful but with friction around my feet and thighs it starts to burn and itch which is no fun at all. And unfortunately having this disease for this long could be bad news for the rest of my organs, which thankfully so far have shown up fine in tests.
So basically at my last rheumatology appointment I was put on the max dose of the mycophenolate with the idea that if this doesn't work we will have to move on to different treatment. There are two options if this happens: a similar immunosuppressant called methotrexate that would basically work like the mycophenolate but maybe magically would do better, or a strong iv infusion called rituximab. Now I have been through my share of weird medical shit but the one thing that still terrifies me is an iv. One of the worst experiences of my life was being hospitalized for a week stuck to an iv in 2012 and the whole time it felt like my arm was being broken. I've always been afraid of needles and in fact my first blood draw at the rheumatologist in Feb I fainted and threw up so now I'm famous with the phlebotomists. So just hearing iv I started to panic a little.
Then the doctor went on to describe the procedure being similar to chemotherapy/biotherapy and included the fun fact of a small risk of deadly anaphylactic shock. I ended up having a full panic attack and sitting on the floor of the office next to an open window while my lovely boyfriend fanned me and got me to drink some water. The doctor kept apologizing for freaking me out but I was just apologizing back like "I have an anxiety disorder it's fine not your fault".
So yeah I go back in on July 12th to see how the max dose and potential last hurrah of my og immunosuppressant works out and meanwhile I am firmly camped in my apartment trying desperately to avoid any flare triggers. I have a spreadsheet now where I rate the rash on each area of my body cause ya girl loves data. My boyfriend Sam has been absolutely wonderful taking care of me throughout this, running urine samples back and forth to the hospital when they kept scheduling my appointments a month apart exactly in line with my period. I am so glad this happened after we moved in together rather than before so I don't have to do this alone or move back in with my parents. My family has tried to understand what's going on but I think only recently started seeing the severity. They've at least stopped trying to guilt me into coming over. Being immunocompromised during a pandemic wasn't enough for them I guess, but minimizing flares so I don't have to do hours of ivs worked. Now we wait.
3 notes
·
View notes
Text
Fwd: Conference: Heraklion_Crete.BiologyAndBiomedicine.Jul20-22
Begin forwarded message:
> From: [email protected]
> Subject: Conference: Heraklion_Crete.BiologyAndBiomedicine.Jul20-22
> Date: 6 April 2024 at 07:00:06 BST
> To: [email protected]
>
>
> Dear Author
>
> You are invited to submit an article in the 4th International Conference
> on Biology and Biomedicine - BIOMEDICINE 2024 Heraklion, Crete Island,
> Greece. July 20-22, 2024.
> https://ift.tt/VlXFMaf
>
>
> Accepted and Presented papers will appear in a Springer Verlag Volume
> Computational Problems in Science and Engineering III
> Editors: Nikos E. Mastorakis, Imre J. Rudas, Yuriy S. Shmaliy
> See our previous volume
> https://ift.tt/ZmdFX34
>
>
>
> Best Papers will be published in the following 3 Journals
>
>
> Molecular Biomedicine (Indexed in ISI Web of Science, Scopus etc)
> Best papers from the conference will appear in this Journal:
> https://ift.tt/Y6vh5W3
>
> Editor-in-Chief
> Yu-quan Wei, PhD, MD, State Key Laboratory of Biotherapy, West China
> Hospital, Sichuan University, China
>
>
>
> Biomedical Journal (Indexed in ISI Web of Science, Scopus etc)
> Best papers from the conference will appear in this Journal:
> https://ift.tt/JLRClGE
>
> Editor-in-Chief
> Prof. Ming-Ling Kuo, Chang Gung University, Taoyuan, Taiwan
>
>
> WSEAS Transactions on Biology and Biomedicine (Indexed in Scopus etc)
> Best papers from the conference will appear in this Journal:
> https://ift.tt/eEfiolH
>
> Editor-in-Chief
> Prof. Nicholas Tritos, Harvard Medical School, Boston, MA, USA
>
> Many Thanks
>
> Kostas Chiotopoulos
>
>
>
> "4th International Conference on Biology and Biomedicine - BIOMEDICINE 2024."
0 notes
Text
Biotherapy (バイオセラピー) , 1986
32 notes
·
View notes
Photo
Order your copy of the fourth edition of the best-selling resource used by more than 101,000 healthcare professionals since 2009 and keep up-to-date on the latest chemotherapy, biotherapy, and targeted agents. This new edition of the Chemotherapy and Biotherapy Guidelines and Recommendations for Practice has been revised and updated to reflect the current procedures and
0 notes
Text
Advancing Glycobiology: Projections and Analysis 2023-2027
Originally Published on: TechnavioGlycobiology Market by Application, Product and Geography - Forecast and Analysis 2023-2027
The Global Glycobiology Market is gearing up for substantial expansion, foreseeing a projected surge of USD 1,473.84 million and an estimated CAGR of 15.06% from 2022 to 2027.
Key Catalysts for Growth
Pharmaceutical and biotechnology sectors are witnessing a notable upswing, propelled by increased R&D activities in glycomics, glycobiology, and proteomics research. Glycobiology is gaining traction in critical areas such as neurobiology, development, immunology, and diverse applications, including biotherapy, antibodies, and heparin analog production.
Carbohydrates intricately bound to glycolipids or glycoproteins play a crucial role in steering the properties and destiny of living cells. The study of glycobiology becomes pivotal in drug discovery, diagnosis, and therapeutic applications, supported by advancements in mass spectrometry for mapping glycan attachment sites and profiling structural variations.
In-Depth Segmentation Analysis
Application Analysis
Drug Discovery and Development: Experiencing substantial growth with the widespread use of glycobiology. Carbohydrates play a pivotal role in biological processes, influencing glycoprotein stability, solubility, and transport.
Product Analysis
Enzymes: Vital in glycobiology, with transferases playing a crucial role in complex carbohydrate generation. These enzymes serve as tools for understanding carbohydrate structure and function.
Instruments: Essential for studying glycans' structure, biology, and function, including microscopes, flow cytometric cell sorting, ELISA, and fluorescent immunohistochemistry. Increasing adoption in disease diagnosis contributes to segment growth.
Regional Analysis
North America is poised to contribute 43% to global market growth, driven by the presence of key pharmaceutical and biopharmaceutical companies, robust healthcare infrastructure, and expanding applications in cancer treatments.
Leading Market Players
Companies deploy diverse strategies like alliances, partnerships, mergers, acquisitions, geographical expansion, and product/service launches. Key players encompass Agilent Technologies Inc., Asparia Glycomics, Bio-Techne Corp, Bruker Corp., CD BioGlyco, Chemily Glycoscience, and more.
Major Drivers, Trends, Challenges, and Customer Landscape
Key Market Drivers
The surge in pharmaceutical companies' R&D expenditure, averaging 15%-20% of revenue, emerges as a significant growth factor. Adoption of pharmaceutical contract packaging minimizes capital and operating costs.
Prominent Market Trends
The escalating demand for glycomics products in drug discovery and development underscores the critical role of glycans in biological processes. Glycans become biomedical hotspots, leading to technological advancements and effective therapies.
Primary Market Challenges
Scarce availability of skilled professionals poses a challenge. Well-trained professionals are imperative for the intricate and risky drug development process in glycobiology.
Customer Landscape
The adoption lifecycle spans from innovators to laggards, encompassing penetration rates in various regions based on key purchase criteria and drivers of price sensitivity.
Segment Overview
The market report predicts revenue growth at global, regional, and country levels, offering insights into trends and opportunities from 2017 to 2027.
Contact us.
#Glycobiology#MarketInsights#BiotechAdvancements#DrugDiscovery#InnovationsInHealthcare#R&D#GlobalMarketTrends
0 notes
Text
Cancer doctor in Ranchi for immunotherapy
Immunotherapy involves using certain parts of a person's immune system to fight cancer. It's also called biologic therapy or biotherapy.
It uses substances made by the body or in a laboratory to boost or restore the immune system's ability to fight cancer.
You can find the cancer doctor in Ranchi at HCG Hospital Ranchi.
0 notes
Text
I'm skeptical anyone on biologic therapy long term can function and have a job and shit.
Like, I know I have deteriorating spine disease, which is also a root cause of a lot of my issues, but at the same time I just had a proper treatment after 5 weeks of it clearing from my system and I forgot just how BAD it makes me feel.
My relatives used to expect me to be feeling better THE DAY OF my treatment when I was always exhausted and sick feeling for sometimes days afterwards.
And every source online says "yeah, with a good (and strict!) treatment regimen, even the sickliest of cr*ps can hold down a job and work in The Machine just like their able bodied counterparts!" But like. I wanna hear it from OTHER chronically ill people.
If you have a moderate to severe autoimmune disease, if you take biotherapy by infusion every 6 weeks WITH daily supplemental anti-inflammatory medications, like... tell me how I'm supposed to feel. How do you feel? Can you work, do you work? Is treating the disease actually worth it if you have to be on these infusions for the next 60 years?
#rant#vent#my medical#medical tw#also i know this sounds like a juvenile rant. ive actually been doing infusions for 10 years (im 25)#but like. i was 15 when i was diagnosed. and i was so sick. and i feel like im just realizing some stuff.
0 notes
Text
Rising Adoption To Treat Ophthalmic Disorders Projected to boost growth of the Amniotic Membrane Market
The global Amniotic Membrane Market is estimated to be valued at US$ 3.62 Bn in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The amniotic membrane is the innermost layer of the placenta which consists of epithelial cells, a thick basement membrane, and an avascular stroma. It possesses properties such as anti-inflammatory, anti-scarring, antimicrobial, anti-angiogenic and pain-relieving properties. This makes it ideal for use in wound healing applications including wounds, burns, ophthalmic disorders, surgical wounds etc. It acts as a biological scaffold and releases growth factors that aid in tissue regeneration. Compared to synthetic skin substitutes or skin grafts, amniotic membrane grafts have lesser probability of developing infection and rejection. With increasing cases of trauma, accidents and chronic wounds worldwide, the demand for effective wound care treatments is growing steadily. This is expected to propel the amniotic membrane market growth over the forecast period.
Market key trends:
One of the key trends gaining traction in the amniotic membrane market is the rising adoption of amniotic membrane for ophthalmic disorders. Amniotic membrane plays a crucial role in ocular surface reconstruction due to its anti-angiogenic, anti-inflammatory and anti-scarring properties. It is increasingly being used to treat ocular disorders like keratitis, corneal ulcers, persistent epithelial defects and corneal perforations. Also, continuous efforts by market players to develop new amniotic membrane products through advanced processing techniques like cryopreservation, lyophilization etc. is expected to drive the market growth. Development of amniotic membrane tissue engineered products for regenerative therapies is another emerging trend in the market.
Porter’s Analysis
Threat of new entrants: Low, as the market requires high capital investment and regulatory approvals for entering.
Bargaining power of buyers: Moderate, as the presence of substitute products provides options to buyers.
Bargaining power of suppliers: High, as raw materials have limited sources of supply globally.
Threat of new substitutes: Moderate, as new substitutes are emerging but amniotic membrane has established use cases over years.
Competitive rivalry: High, as the key players compete on the basis of quality, price and technology.
Key Takeaways
The global amniotic membrane market size is expected to witness high growth at a CAGR of 13% over the forecast period 2023 to 2030, due to increasing cases of ocular surface disorders.
Regional analysis: North America dominates the global market currently owing to increasing healthcare expenditure and growing patients' population. However, Asia Pacific is expected to grow at the fastest pace during the forecast period with rising medical tourism and improving healthcare infrastructure in emerging countries.
Key players operating in the amniotic membrane market include Smith & Nephew, Applied Biologics, Organogenesis Holdings Inc., Osiris Therapeutics, Inc., Alliqua BioMedical, Inc., Amnio Technology, LLC, Next Biosciences, Integra LifeSciences, MiMedx, LifeCell International, Human Regenerative Technologies, LLC, Amniox Medical, Inc, Skye Biologics Inc., Wright Medical, TissueTech, Katena Products, Inc., NuVision Biotherapies, Surgenex, and Ventris Medical. Key players are focused on new product launches and regulatory approvals to strengthen their market position.
0 notes
Text
So Sam's starting chemo today after all even though her platelet count is still low; they just don't want to delay it any more than they have to because of how hard and fast acute leukemia hits. This means she may end up getting more than the average of 50 units of platelets a chemo patient usually receives.
Every chemo patient gets between 30 and 50 units of platelets transfused over the course of their treatment. Which is a lot of platelets! Whole blood and platelet donations help a whole lot. I'm not even asking specifically for Sam, blood donation is just a general good.
To that end! AABB (Association for the Advancement of Blood and Biotherapies) has a donation center locator that you can use to find a spot near you in the US. If it's something you can do, please consider it, or let other people know how and where in your area. I know I sound like an ASPCA ad but at this point literally half my family has been a regular transfusion recipient so it's a little personal.
a sleepy boy tax:
0 notes
Text
Global Oncology Devices Market Outlook Through 2023-2032
The Business Research Company’s Oncology Devices Global Market Report 2023 is the most detailed report available on the market, including broad forecast periods and multiple geographies. The report covers the historic period – 2010-2021, and the forecast period – 2023-2032. The Oncology Devices Global Market Report 2023 evaluates oncology devices market size, growth rate, drivers, trends, and major companies.
The report provides a global perspective by covering 60 geographies and focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Free Sample Of The Report (Includes Graphs And Tables):
The global oncology devices market size grew from $107.81 billion in 2022 to $128.33 billion in 2023 at a compound annual growth rate (CAGR) of 19.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global oncology devices is expected to grow from $250.74 billion in 2027 at a CAGR of 18.2%.
The oncology devices market segments in the report are:
1) By Device Type: Brachytherapy Devices, Endoscopic Devices
2) By Therapy: Chemotherapy, Hormone Therapy, Biotherapy/Immunotherapy, Radiation Therapy
3) By End User: Hospitals, Cancer Research Institutes, Other End Users
Get More Information On The Oncology Devices Market Report:
The table of contents in TBRC’s oncology devices market report includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
0 notes
Last Seen Blogs
adbros
Ad Bros
tolicandco
readig fics at school ft. poor life choices
cat--called
@Cat_Called
music-base-whom
Untitled
little-sundays
M I L K